Jasper Therapeutics (JSPR) has provided an update.
Anna French, D.Phil., resigned from the Board of Directors at Jasper Therapeutics, Inc., with no disputes cited, and was succeeded by Svetlana Lucas, Ph.D., on June 18, 2024. Dr. Lucas brings extensive experience in biopharmaceuticals, having held roles at Scribe Therapeutics, Tizona Therapeutics, and Amgen. She has been granted an option to purchase shares and will receive standard compensation for her directorship. Her appointment, free from any insider relationships or reportable transactions, was publicly announced by the company.
For detailed information about JSPR stock, go to TipRanks’ Stock Analysis page.
